Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Abbie Stockard declared victory over 51 other contestants. She credited her relationship with God for giving her the drive to ...

Any lingering doubts over the feasibility of rolling out population-based cancer registries in low-income and middle-income ...

Statistics on the representation of women in the CAF as of December 2024 A summary of women's representation rates for officers and non-commissioned members (NCMs) in the Regular Force and Primary ...

Our IoS methods and sources pages provide more information on the data that underpin these statistics; of particular note is our GDP(o) data sources catalogue. Value Added Tax (VAT) data are also ...

We would like to use cookies to collect information about how you use ons.gov.uk. We use this information to make the website work as well as possible and improve our services.

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

What is a cystic hygroma? A cystic hygroma — or lymphangioma — is a birth defect that appears as a sac-like structure with a thin wall that most commonly occurs in the head and neck area of an infant.